Ferring Pharmaceuticals A/S — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

3 Recruiting

4 Completed trials

11 Countries active

10 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III/IV

Phase I

Phase I (Other)

Phase I (FiH)

Phase III: 2 Phase II: 1 Phase I/II: 1 Phase III/IV: 1 Phase I: 1 Phase I (Other): 2 Phase I (FiH): 1

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

NADOFARAGENE FIRADENOVEC 3 FOLLITROPIN DELTA 2 ALLOGENEIC REGULATORY MACROPHAGES 1 CHORIOGONADOTROPIN ALFA 1 GANIRELIX 1 MENOTROPHIN 1 PEMBROLIZUMAB 1 TRIPTORELIN ACETATE 1

All trials

9 total

MENOPUR and REKOVELLE in Women UnderGoing an assisted reproductive technology cycle Pending

2022-500308-23-00 Phase III/IV 2 countries CHORIOGONADOTROPIN ALFA; FOLLITROPIN DELTA; GANIRELIX; MENOTROPHIN; TRIPTORELIN …
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to the Renal Pelvis (LUNAR) Pending

2024-514360-70-00 Phase I/II 3 countries NADOFARAGENE FIRADENOVEC
A study comparing nadofaragene firadenovec with standard of care in adults with an increased risk that non-muscle invasive bladder cancer ma… Recruiting

2024-512029-10-00 Phase III 6 countries NADOFARAGENE FIRADENOVEC
Effect of TRI-001 in patients with chronic limb threatening ischemia Recruiting

2024-517765-16-00 Phase I (FiH) 1 country ALLOGENEIC REGULATORY MACROPHAGES
A study to learn about nadofaragene firadenovec given alone or together with gemcitabine and docetaxel or, pembrolizumab in adults with non-… Recruiting

2024-512177-27-01 Phase III 5 countries NADOFARAGENE FIRADENOVEC; PEMBROLIZUMAB
An exploratory study to investigate the effect of FE 999302 when given during different time periods to women undergoing controlled ovarian … Ended

2023-508149-42-00 Phase I (Other) 5 countries
An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulation Ended

2023-507630-25-00 Phase I (Other) 5 countries
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple doses Ended

2023-507882-24-00 Phase I 1 country
A trial to compare efficacy and safety of follitropin delta versus placebo (inactive treatment) in the treatment of men with idiopathic infe… Ended

2023-508430-34-00 Phase II 6 countries FOLLITROPIN DELTA

Showing 1–9 of 9 trials

← All sponsors A–Z